

Literatur

1. Mönch E, Link R. Diagnostik und Therapie bei angeborenen Stoffwechselstörungen. SPS Publications, Heilbronn (2006)
2. Fernandes J, Saudubray JM, van den Gerghe G et al. Inborn Metabolic Diseases. Springer Verlag, Heidelberg (2006)
3. Loeber JG (2007) Neonatal screening in Europe; the situation in 2004. *J Inherit Metab Dis* 4: 430–438
4. Folling I (1994) The discovery of phenylketonuria. *Acta Paediatr Suppl* 407: 4–10
5. Christ SE (2003) Asbjørn Følling and the discovery of phenylketonuria. *J Hist Neurosci* 121: 44–54
6. Scriver CR, Kaufmann S, Eisensmith RC et al. The hyperphenylalaninemias. In: Scriver RC (Hg). *The metabolic and molecular basis of inherited disease*. McGraw-Hill, New York (1998), S. 1015–1075
7. Pardridge WM (1998) Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. *Neurochem Res* 235: 635–644
8. Surtees R, Blau N (2000) The neurochemistry of phenylketonuria. *Eur J Pediatr* 159(Suppl 2): S109–S113
9. Ceglarek U, Muller P, Stach B et al. (2000) Validation of the phenylalanine/tyrosine ratio determined by tandem mass spectrometry: sensitive newborn screening for phenylketonuria. *Clin Chem Lab Med* 7: 693–697
10. Chace DH, Sherwin JE, Hillman SL et al. (1998) Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. *Clin Chem* 12: 2405–2409
11. Fisberg RM, da Silva-Fernandes ME, Schmidt BJ et al. (1999) Nutritional evaluation of children with phenylketonuria. *Sao Paulo Med J* 5: 185–191
12. von Schnackenburg K, Zoubeck K (2002) Richtlinien zur Organisation und Durchführung des Neugeborenen Screenings auf angeborene Stoffwechselstörungen und Endokrinopathien in Deutschland. *Monatsschrift für Kinderheilkunde* 150: 1424–1440
13. Nennstiel-Ratzel U, Genzel-Boroviczeny O, Böhles H et al. (2012) Leitlinie Neugeborenen-Screening auf angeborenen Stoffwechselstörungen und Endokrinopathien. AWMF-online. URL: www.awmf.org/leitlinien/detail/ll/024-012.html Zugriff 20.06.15
14. National Institutes of Health (2001) Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000. *Pediatrics* 108: 972–982
15. Blau N. *Phenylketonuria and BH4 Deficiencies*. International Medical Publishers, London/Boston (2010)
16. Smith I, Beasley MG, Ades AE (1990) Intelligence and quality of dietary treatment in phenylketonuria. *Arch Dis Child* 5: 472–478
17. Burgard P, Bremer HJ, Buhrdel P et al. (1999) Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. *Eur J Pediatr* 158: 46–54
18. Wendel U, Ullrich K, Schmidt H et al. (1990) Six-year follow up of phenylalanine intakes and plasma phenylalanine concentrations. *Eur J Pediatr* 149(Suppl 1): S13–S16
19. Deutsche Gesellschaft für Ernährung (DGE), Österreichische Gesellschaft für Ernährung (ÖGE), Schweizerische Gesellschaft für Ernährungsforschung (SGE), Schweizerische Vereinigung für Ernährung (Hg). *Referenzwerte für die Nährstoffzufuhr*. 2. Aufl., 1. Ausgabe, Bonn (2015)
20. WHO. *Protein and amino acid requirements in human nutrition: report of a joint FAO/WHO/UNU expert consultation*. Geneva, Switzerland (2002)
21. Monch E, Herrmann ME, Brosicke H et al. (1996) Utilisation of amino acid mixtures in adolescents with phenylketonuria. *Eur J Pediatr* 155(Suppl 1): S115–S120
22. Herrmann ME, Brosicke HG, Keller M et al. (1994) Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report. *Eur J Pediatr* 153: 501–503
23. Gropper SS, Acosta PB (1991) Effect of simultaneous ingestion of L-amino acids and whole protein on plasma amino acid and urea nitrogen concentrations in humans. *N J Parenter Enteral Nutr* 15: 48–53
24. Elmadfa I, Leitzmann C. *Ernährung des Menschen*. Ulmer, Stuttgart (1988), S. 155–158
25. Müller E. *Praktische Diätetik in der Pädiatrie. Grundlagen für die Ernährungstherapie*. SPS Verlagsgesellschaft mbH, Heilbronn (2003)
26. Greve LC, Wheeler MD, Green-Burgeson DK et al. (1994) Breast-feeding in the management of the newborn with phenylketonuria: a practical approach to dietary therapy. *J Am Diet Assoc* 94: 305–309
27. Motzfeldt K, Lilje R, Nylander G (1999) Breast-feeding in phenylketonuria. *Acta Paediatr Suppl* 88: 25–27
28. Arbeitsgemeinschaft pädiatrische Diätetik. *Nährwerttabelle für die Ernährung bei angeborenen Störungen des Aminosäurestoffwechsels*. SHS Gesellschaft für klinische Ernährung, Heilbronn (2009)
29. Ahring K, Belanger-Quintana A, Dokoupil K et al. (2009) Dietary management practices in phenylketonuria across European centres. *Clin Nutr* 28: 231–236
30. Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. *Int J Adolesc Med Health* 16: 41–45
31. MacDonald A, Rylance G, Davies P et al. (2003) Free use of fruits and vegetables in phenylketonuria. *J Inherit Metab Dis* 26: 327–338
32. Rohde C, Mutze U, Weigel JF et al. (2012) Unrestricted consumption of fruits and vegetables in phenylketonuria: no major impact on metabolic control. *Eur J Clin Nutr* 66: 633–638
33. Rohde C, Mutze U, Schulz S et al. (2014) Unrestricted fruits and vegetables in the PKU diet: a 1-year follow-up. *Eur J Clin Nutr* 68: 401–403
34. Rohde C, Thiele AG, Mutze U et al. (2014) Simplifying the diet for patients with phenylketonuria (PKU): unrestricted consumption of fruit and vegetables. *Ernährungs Umschau* 61: 178–180
35. Zimmermann M, Jacobs P, Fingerhut R et al. (2012) Positive effect of a simplified diet on blood phenylalanine control in different phenylketonuria variants, characterized by newborn BH4 loading test and PAH analysis. *Mol Genet Metab* 106: 264–268
36. Rohde C, Thiele AG, Och U et al. (2015) Effect of dietary regime on metabolic control in phenylketonuria: Is exact calculation of phenylalanine really necessary? *Mol Genet Metab Reports* 5: 36–41
37. Weglage J, Fromm J, van Teeffelen-Heithoff A et al. (2013) Neurocognitive functioning in adults with phenylketonuria: results of a long term study. *Mol Genet Metab* 110(Suppl): S44–S48
38. Bilginsoy C, Waitzman N, Leonard CO et al. (2005) Living with phenylketonuria: perspectives of patients and their families. *J Inherit Metab Dis* 28: 639–649
39. Koch R, Levy HL, Matalon R et al. (1993) The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. *Am J Dis Child* 147: 1224–1230
40. Bickel H (1953) The effects of a phenylalanine-free and phenylalanine-poor diet in phenylpyruvic oligophrenia. *Exp Med Surg* 12: 114–117
41. Bickel H, Gerrad J, Hickmann EM (1954) The

- influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonic child. *Acta Paediatr* 43: 64–77
42. Burnett JR (2007) Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. *IDrugs* 10: 805–813
43. Lee P, Treacy EP, Crombez E et al. (2008) Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. *Am J Med Genet A* 146A: 2851–2859
44. Gersting SW, Staudigl M, Truger MS et al. (2010) Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. *J Biol Chem* 285: 30686–30697
45. Muntau AC, Roschinger W, Habich M et al. (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. *N Engl J Med* 347: 2122–2132
46. Hennermann JB, Bührer C, Blau N et al. (2005) Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. *Mol Genet Metab* 86(Suppl 1): S86–S90
47. Lambruschini N, Perez-Duenas B, Vilaseca MA et al. (2005) Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. *Mol Genet Metab* 86(Suppl 1): S54–S60
48. Burlina A, Blau N (2009) Effect of BH(4) supplementation on phenylalanine tolerance. *J Inher Metab Dis* 32: 40–45
49. Trefz FK, Burton BK, Longo N et al. (2009) Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. *J Pediatr* 154: 700–707
50. Harding C (2008) Progress toward cell-directed therapy for phenylketonuria. *Clin Genet* 74: 97–104
51. Ding Z, Georgiev P, Thony B (2006) Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. *Gene Ther* 13: 587–593
52. Ding Z, Harding CO, Thony B (2004) State-of-the-art 2003 on PKU gene therapy. *Mol Genet Metab* 81: 3–8
53. Thony B (2010) Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle. *J Inher Metab Dis* 33: 677–680
54. Belanger-Quintana A, Burlina A, Harding CO et al. (2011) Up to date knowledge on different treatment strategies for phenylketonuria. *Mol Genet Metab* 104(Suppl): S19–S25
55. Sarkissian CN, Kang TS, Gamez A et al. (2011) Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria. *Mol Genet Metab* 104: 249–254